• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过基于琼脂的筛选方法发现针对铜绿假单胞菌和其他革兰氏阴性ESKAPE病原体的强效溶菌酶。

Discovery of potent endolysins against Pseudomonas aeruginosa and other gram-negative ESKAPE pathogens by an agar-based screening method.

作者信息

Oberbauer Vera, Mutti Michele, Schwebs Timo, Durica-Mitic Svetlana, Visram Zehra, Kestemont Donaat, Badarau Adriana, Corsini Lorenzo

机构信息

BioNTech R&D (Austria) GmbH, Vienna, Austria.

出版信息

Sci Rep. 2025 Aug 11;15(1):29351. doi: 10.1038/s41598-025-14753-y.

DOI:10.1038/s41598-025-14753-y
PMID:40790072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12339961/
Abstract

Antibiotic resistance is a growing concern, and there is an urgent need for alternative treatments. A proposed solution includes endolysins. Naturally occurring endolysins have limited activity against Gram-negative bacteria due to the presence of an outer membrane. Previous agar-based screening methods did not consider this and screened for activity on autoclaved cell debris. In this study, we used a soft-agar-based screening method to identify endolysins targeting Pseudomonas aeruginosa. This method enabled us to screen for activity of endolysins on live Pseudomonas aeruginosa, taking the outer membrane into account. The application of this randomized forward screening method led to the discovery of three highly bactericidal endolysins, L0779, L0782, and L0799. These endolysins displayed a broad spectrum of activity against other Gram-negative bacterial species. We report minimal inhibitory concentrations (MICs) for endolysins acting on multiple Gram-negative ESKAPE species, with MICs for L0782 on Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii ranging from 4 to 16 µg/mL. In summary, our screening method enables rapid identification of endolysins with broad-spectrum activity against Gram-negative bacteria. These show potential for further development as alternative treatments for antibiotic-resistant infections.

摘要

抗生素耐药性问题日益严重,迫切需要替代治疗方法。一种提议的解决方案包括内溶素。由于存在外膜,天然存在的内溶素对革兰氏阴性菌的活性有限。以前基于琼脂的筛选方法未考虑到这一点,而是在高压灭菌的细胞碎片上筛选活性。在本研究中,我们使用基于软琼脂的筛选方法来鉴定靶向铜绿假单胞菌的内溶素。该方法使我们能够在考虑外膜的情况下,筛选内溶素对活的铜绿假单胞菌的活性。这种随机正向筛选方法的应用导致发现了三种高度杀菌的内溶素,即L0779、L0782和L0799。这些内溶素对其他革兰氏阴性菌具有广泛的活性。我们报告了作用于多种革兰氏阴性ESKAPE菌属的内溶素的最低抑菌浓度(MIC),L0782对铜绿假单胞菌、大肠杆菌、肺炎克雷伯菌和鲍曼不动杆菌的MIC范围为4至16μg/mL。总之,我们的筛选方法能够快速鉴定对革兰氏阴性菌具有广谱活性的内溶素。这些内溶素显示出作为抗生素耐药感染替代治疗方法进一步开发的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/e22be4deee1e/41598_2025_14753_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/77af112ff0ea/41598_2025_14753_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/5db7f9ff09c7/41598_2025_14753_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/83a47568199e/41598_2025_14753_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/b01a4cc27915/41598_2025_14753_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/e22be4deee1e/41598_2025_14753_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/77af112ff0ea/41598_2025_14753_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/5db7f9ff09c7/41598_2025_14753_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/83a47568199e/41598_2025_14753_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/b01a4cc27915/41598_2025_14753_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7f/12339961/e22be4deee1e/41598_2025_14753_Fig5_HTML.jpg

相似文献

1
Discovery of potent endolysins against Pseudomonas aeruginosa and other gram-negative ESKAPE pathogens by an agar-based screening method.通过基于琼脂的筛选方法发现针对铜绿假单胞菌和其他革兰氏阴性ESKAPE病原体的强效溶菌酶。
Sci Rep. 2025 Aug 11;15(1):29351. doi: 10.1038/s41598-025-14753-y.
2
Development of Chimera AMP-Endolysin with Wider Spectra Against Gram-Negative Bacteria Using High-Throughput Assay.利用高通量检测技术开发对革兰氏阴性菌具有更广泛谱的嵌合AMP-内溶素
Viruses. 2025 Jan 30;17(2):200. doi: 10.3390/v17020200.
3
Nationwide surveillance of carbapenem-resistant Gram-negative pathogens in the Lebanese environment.黎巴嫩环境中耐碳青霉烯革兰氏阴性病原体的全国性监测。
Appl Environ Microbiol. 2025 Jul 23;91(7):e0193224. doi: 10.1128/aem.01932-24. Epub 2025 Jun 10.
4
LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria.LysJEP8:一种有前途的新型溶菌素,可用于对抗多种耐药革兰氏阴性菌。
Microb Biotechnol. 2024 Jun;17(6):e14483. doi: 10.1111/1751-7915.14483.
5
Large-scale combination screens reveal small-molecule sensitization of antibiotic-resistant gram-negative ESKAPE pathogens.大规模联合筛选揭示了抗生素耐药革兰氏阴性ESKAPE病原体的小分子致敏作用。
Proc Natl Acad Sci U S A. 2025 Apr;122(13):e2402017122. doi: 10.1073/pnas.2402017122. Epub 2025 Mar 24.
6
Dissecting the inhibitory activity of Burkholderia orbicola against Gram-positive and - negative multidrug-resistant bacteria.剖析圆褐伯克霍尔德菌对革兰氏阳性和阴性多重耐药菌的抑制活性。
PLoS One. 2025 Jun 30;20(6):e0326906. doi: 10.1371/journal.pone.0326906. eCollection 2025.
7
Carbapenem-Resistant Gram-Negative Bacterial Infections at a Tertiary Health Care Center in Nepal: An Observational Study.尼泊尔一家三级医疗中心的耐碳青霉烯类革兰氏阴性菌感染:一项观察性研究。
JNMA J Nepal Med Assoc. 2025 Jan;63(281):47-51. doi: 10.31729/jnma.8862. Epub 2025 Jan 31.
8
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
9
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.根除囊性纤维化患者体内铜绿假单胞菌的抗生素策略。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD004197. doi: 10.1002/14651858.CD004197.pub5.
10
Novel broadly reactive monoclonal antibody protects against infection.新型广泛反应性单克隆抗体可预防感染。
Infect Immun. 2025 Jan 31;93(1):e0033024. doi: 10.1128/iai.00330-24. Epub 2024 Dec 13.

本文引用的文献

1
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.《2024年世界卫生组织细菌重点病原体清单》:一项用于指导针对抗菌药物耐药性的研究、开发及公共卫生策略的优先级排序研究。
Lancet Infect Dis. 2025 Apr 11. doi: 10.1016/S1473-3099(25)00118-5.
2
Development of Chimera AMP-Endolysin with Wider Spectra Against Gram-Negative Bacteria Using High-Throughput Assay.利用高通量检测技术开发对革兰氏阴性菌具有更广泛谱的嵌合AMP-内溶素
Viruses. 2025 Jan 30;17(2):200. doi: 10.3390/v17020200.
3
You get what you test for: The killing effect of phage lysins is highly dependent on buffer tonicity and ionic strength.
有检必应:噬菌体裂解酶的杀菌效果高度依赖于缓冲液的渗透压和离子强度。
Microb Biotechnol. 2024 Jul;17(7):e14513. doi: 10.1111/1751-7915.14513.
4
The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia.工程溶菌酶 CF-370 对体外耐抗生素革兰氏阴性病原体具有活性,并与美罗培南在实验性铜绿假单胞菌肺炎中具有协同作用。
J Infect Dis. 2024 Aug 16;230(2):309-318. doi: 10.1093/infdis/jiae027.
5
Gram-negative endolysins: overcoming the outer membrane obstacle.革兰氏阴性内溶素:克服外膜障碍。
Curr Opin Microbiol. 2024 Apr;78:102433. doi: 10.1016/j.mib.2024.102433. Epub 2024 Feb 12.
6
The global epidemiology of ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa: A systematic review and meta-analysis.多药耐药铜绿假单胞菌引起呼吸机相关性肺炎的全球流行病学:系统评价和荟萃分析。
Int J Infect Dis. 2024 Feb;139:78-85. doi: 10.1016/j.ijid.2023.11.023. Epub 2023 Nov 26.
7
Design, Screening, and Characterization of Engineered Phage Endolysins with Extracellular Antibacterial Activity against Gram-Negative Bacteria.设计、筛选和鉴定具有抗革兰氏阴性菌胞外抗菌活性的工程噬菌体溶菌素。
Appl Environ Microbiol. 2023 Jul 26;89(7):e0058123. doi: 10.1128/aem.00581-23. Epub 2023 Jun 20.
8
Characterization of Three Different Endolysins Effective against Gram-Negative Bacteria.三种不同内切溶菌酶对革兰氏阴性菌的作用特性研究。
Viruses. 2023 Mar 4;15(3):679. doi: 10.3390/v15030679.
9
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担:系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
10
The Advantages and Challenges of Using Endolysins in a Clinical Setting.在临床环境中使用内切溶素的优势和挑战。
Viruses. 2021 Apr 15;13(4):680. doi: 10.3390/v13040680.